Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias

Expert Review of Neurotherapeutics

Volumn 15, Issue 2, 2014, Pages 207-213

  Stathis, Pantelis ^a   Konitsiotis, Spiridon ^b   Antonini, Angelo ^c  

^a Mediterraneo Hospital   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Continuous dopaminergic stimulation; Dopamine agonists; Levodopa induced dyskinesias; Long term results; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ANTIPARKINSON AGENT;

ADVERSE DRUG REACTION; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DYSKINESIA; EARLY INTERVENTION; HUMAN; LEVODOPA INDUCED DYSKINESIAS; MONOTHERAPY; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; SURVIVAL RATE; ANIMAL; COMPLICATION; DYSKINESIA, DRUG-INDUCED; TIME;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; TIME;

EID: 84921725435     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1001747     Document Type: Review

References (61)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations and disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, editros, Movement disorders. Volume 6. Butterworth, London, UK; 1982. p. 96-105
2. Nutt JG. Levodopa-induced dyskinesias: review, observations, and speculations. Neurology 1990;40:340-5
3. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-305
4. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-89
5. Smith LA, Jackson MJ, Hansard MJ, et al. Effect of pulsatile administration of levodopa on dyskinesias induction in drug-naïve MPTP-treated common marmosets: effect of dose, Frequency of administration and brain exposure. Mov Disord 2003;18:487-95
6. Chase TN, Baronti F, Fabbrini G, et al. Rationale for continous dopaminergic therapy of Parkinson's disease. Neurology 1989;39:7-10
7. Olanow WC, Obeso JA, Stocchi F. Continous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
8. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(Suppl 3):6-12
9. Rinne UK. Early dopamine agonist therapy in Parkinson's disease. Mov Disord 1989;4(Suppl 1):86-94
10. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's Disease. Neurology 1994;44(Suppl 6):15-18
11. Maratos EC, Jackson MJ, Pearce RK, et al. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrixjacchus). Exp Neurol 2003;179:90-102
12. Jenner P. Preventing and controlling dyskinesias in Parkinson's disease-A view of current knowledge and future opportunities. Mov Disord 2008;23(Suppl 3):585-98
13. Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. Eur J Neurol 2012;19:1502-8
14. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303:791-804
15. Misu Y, Goshima Y, Miyamae T. Is DOPA a neurotransmitter? Trends Pharmacol Sci 2002;23(6):262-8
16. Aubert I, Guigoni C, Ha˚kansson K, et al. Increased D1 receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005;57:17-26
17. Rascol O, Nutt JG, Blin O, et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 2001;58:249-54
18. Visanji NP, Fox SH, Johnston T, et al. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiol Dis 2009;35(2):184-92
19. Chondrogiorgi M, Tatsioni A, Reichmann H, Konitsiotis S. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol 2014;21:433-40
20. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET Study. Mov Disord 2006;21:343-53
21. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;7:1044-53
22. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-91
23. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55(Suppl 1):23-30
24. Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):2-41
25. Schapira AHV, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013;12:747-55
26. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Ann Neurol 2010;68:18-27
27. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006;21:1844-50
28. Constantinescu R, Romer M, McDermott MP, et al. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2007;22:1317-19
29. PSG CALM cohort investigators. Long-term effect of initiating pramipexole vs levodopa in early parkinson disease. Arch Neurol 2009;66(5):563-70
30. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-17
31. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008;71:474-80
32. Honing H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74
33. Antonini A, Albin RL. Dopaminergic treatment and nonmotor features of Parkinson disease. The horse lives. Neurology 2013;80:784-5
34. Leentjens AFG. The role of dopamine agonists in the treatment of depression in patients with parkinson's disease. Drugs 2011;71:273-86
35. Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013;80:800-9
36. Brown RG, Landau S, Hindle JV, et al. Depression and anxiety related subtypes in Parkinson's disease. J Neurol Neurosurg Psychiatry 2011;82:803-9
37. Antonini A, Tolosa E, Misuno Y, et al. Reassessment of risks and benefits of dopamine agonists in Parkinson' s disease. Lancet Neurol 2009;8:929-37
38. Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson's disease therapeutics. Mov Disord 2011;26:1072-82
39. Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res 1998;800:269-74
40. Richtand NM. Behavioral sensitization, alternative splicing, and D3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 2006;31:2368-75
41. Sokoloff P, Martres MP, Giros B, et al. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 1992;43:659-66
42. Castrioto A, Kistner A, Klinger H, et al. Psychostimulant effect of levodopa: reversing sensitisation is possible. J Neurol Neurosurg Psychiatry 2013;84(1):18-22
43. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome inParkinson's disease. Arch Neurol 2010;67:58-63
44. Thobois S, Ardouin C, Lhommée E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133:1111-27
45. Oertel WH, Berardelli A, Bloem BR, et al. Early (uncomplicated) Parkinson's Disease. In: Gilhus NE, Barnes MP, editors, EFNS European Handbook of Neurological Management. Volume 1. Blackwell Publishing Ltd, UK; 2011. p. 217-36
46. Politis M. Neuroimaging in Parkinson disease:from research setting to clinical practice. Nat Rev Neurol 2014;10(12):708-22
47. Antonini A, Schwarz J, Oertel WH, et al. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C] raclopride. Mov Disord 1997;12(1):33-8
48. dela Fuente-Fernández R, Sossi V, Huang Z, et al. Levodopa-inducedchangesinsynaptic dopaminelevelsincreasewith progressionofParkinson'sdisease: implicationsfordyskinesias. Brain 2004;127:2747-54
49. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram bodyweight. Eur J Neurol 2008;15:493-6
50. Fahn S, Oakes D, Shoulson I, et al. PSG Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508
51. Tsironis C, Marselos M, Evangelou A, Konitsiotis S. The course of dyskinesia induction by different treatment schedules of levodopa in parkinsonian rats: is continuous dopaminergic stimulation necessary? Mov Disord 2008;23:950-7
52. Olanow WC, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesias and the wearing-off in Parkinson's disease. Mov Disord 2013;28:1064-71
53. Parkkinen L, O'Sullivan SS, Kuoppamäki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 2011;77:1420-6
54. Agid Y. Levodopa: is toxicity a myth? Neurology 1998;50(4):858-63
55. Marin C, Bonastre M, Mengod G, et al. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats. Neurobiol Dis 2014;64:36-47
56. Schüepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's Disease with Early Motor Complications. N Engl J Med 2013;368:610-22
57. Strauss I, Kalia SK, Lonzano AM. Where we are with surgical therapies for Parkinson's disease? Parkisonism Relat Disord 2014;20(Suppl 1):187-91
58. Antonini A, Barone P. Dopamine agonist-based strategies in the treatment of Parkinson's disease. Neurol Sci 2008;29:371-4
59. Olanow WC, Stern MB, KapilSethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72(Suppl 4):1-136
60. Calandrella D, Antonini A. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):120-2
61. Chaudhuri RK, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm 2013;120:1305-20